DNA was isolated from patient tumor biopsies and mutations in mTOR genes were assayed by NGS. Limited clinical benefit with targeting this pathway in advanced UC. Phase II, single-arm, non-randomized study with everolimus in refractory UC showed minimal response with median PFS 2.6 months, median OS 8.3 months, and 2 responses seen in 45 patients. Here, MTOR is linked to neoplasm.